Ablynx and P&G in Nanobody drug partnership

Related tags Signal transduction

Drug discovery company Ablynx is to enter into a partnership with
Proctor and Gamble Pharmaceuticals. The agreement will make use of
Ablynx's Nanobody platform to develop drug candidates against a
G-protein coupled receptor (GPCR) target specified by P&GP.

Under terms of the partnership, P&GP will provide Ablynx with research and development funding, pre-determined milestone payments, and royalties upon commercialisation.

Ablynx will be responsible for discovering Nanobodies that meet a pre-defined product profile. P&GP will assume responsibility for the pre-clinical and clinical development of lead Nanobodies, as well as the commercialisation of any resulting drug products.

Simon Kerry, Director of Business Development at Ablynx​ told DrugResearcher.com:"Our technology was unique in the sense that it has a structure that can bind into enzyme active sites and receptor clefts, expanding the range of disease targets that can be addressed."

"The partnership was formed between ourselves and P&GP because they had a G-protein coupled receptor (GPCR) target that we felt our Nanobody technology was suitable for."

Nanobodies are a novel class of therapeutics that combines the advantages of conventional antibodies with key features of small-molecule drugs. Nanobodies can address therapeutic targets not easily recognized by conventional antibodies, including active sites of enzymes and receptors, such as GPCRs. Nanobodies can also be produced cost-effectively at large-scale, has a long shelf-life, and can be administered through non-injectable means.

Since commencing operations in 2002, Ablynx has generated Nanobody pre-clinical programs in the areas of inflammation and thrombosis and several discovery programs in the areas of oncology and CNS.

Kerry added that: "At the moment the Nanobodies are in preclinical development to treat rheumatoid arthritis, inflammatory bowel disease and thrombosis. Human trials are expected to commence in the first half of 2006."

Related topics Clinical Development

Related news

Show more

Follow us


View more